The effect of daunomycin on human cells in vivo and in vitro

Jacqueline Whang‐Peng, Brigid G. Leventhal, John W. Adamson, Seymour Perry

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Cytogenetic and morphologic abnormalities in bone marrow and peripheral blood and biochemical changes in peripheral blood leukocytes were studied after in‐vivo and in‐vitro treatment with daunomycin. Seven patients with acute lymphocytic or granulocytic leukemia were studied; the total dose varied from 80 to 420 mg/m2. The highest percentage of major chromosomal aberrations (80 to 90%) appeared right after treatment in vivo. These aberrations disappeared within 1 or 2 weeks and consisted of chromatid breaks, fragments, chromatid exchanges, ring chromosomes, dicentrics or extensive fragments. Prominent morphologic abnormalities included megaloblastic transformation of both the myeloid and erythroid series and increased cytoplasmic vacuolization. Aneuploid cells lines from two patients showed less change after daunomycin treatment than did normal diploid cells. The daunomycin dose threshold in vitro was narrow: 3 μg/ml of culture caused death of the entire cell population, while 0.03 μg/ml of culture produced little chromosomal damage. The in‐vitro studies on normal human lymphocytes indicate that daunomycin affects RNA and DNA synthesis and that it interferes with the cell cycle during the G2 period. This drug appears to have the unique capacity to delay the onset of mitosis in cells which have already synthesized DNA.

Original languageEnglish
Pages (from-to)113-121
Number of pages9
JournalCancer
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 1 1969
Externally publishedYes

Fingerprint

Daunorubicin
Chromatids
Chromosome Aberrations
Ring Chromosomes
Myeloid Leukemia
DNA
Aneuploidy
Diploidy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mitosis
Cell Cycle
Leukocytes
Cell Death
Therapeutics
Bone Marrow
Lymphocytes
RNA
Cell Line
In Vitro Techniques
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The effect of daunomycin on human cells in vivo and in vitro. / Whang‐Peng, Jacqueline; Leventhal, Brigid G.; Adamson, John W.; Perry, Seymour.

In: Cancer, Vol. 23, No. 1, 01.01.1969, p. 113-121.

Research output: Contribution to journalArticle

Whang‐Peng, Jacqueline ; Leventhal, Brigid G. ; Adamson, John W. ; Perry, Seymour. / The effect of daunomycin on human cells in vivo and in vitro. In: Cancer. 1969 ; Vol. 23, No. 1. pp. 113-121.
@article{40ab8ec7efa0495b916507616d2efdf7,
title = "The effect of daunomycin on human cells in vivo and in vitro",
abstract = "Cytogenetic and morphologic abnormalities in bone marrow and peripheral blood and biochemical changes in peripheral blood leukocytes were studied after in‐vivo and in‐vitro treatment with daunomycin. Seven patients with acute lymphocytic or granulocytic leukemia were studied; the total dose varied from 80 to 420 mg/m2. The highest percentage of major chromosomal aberrations (80 to 90{\%}) appeared right after treatment in vivo. These aberrations disappeared within 1 or 2 weeks and consisted of chromatid breaks, fragments, chromatid exchanges, ring chromosomes, dicentrics or extensive fragments. Prominent morphologic abnormalities included megaloblastic transformation of both the myeloid and erythroid series and increased cytoplasmic vacuolization. Aneuploid cells lines from two patients showed less change after daunomycin treatment than did normal diploid cells. The daunomycin dose threshold in vitro was narrow: 3 μg/ml of culture caused death of the entire cell population, while 0.03 μg/ml of culture produced little chromosomal damage. The in‐vitro studies on normal human lymphocytes indicate that daunomycin affects RNA and DNA synthesis and that it interferes with the cell cycle during the G2 period. This drug appears to have the unique capacity to delay the onset of mitosis in cells which have already synthesized DNA.",
author = "Jacqueline Whang‐Peng and Leventhal, {Brigid G.} and Adamson, {John W.} and Seymour Perry",
year = "1969",
month = "1",
day = "1",
doi = "10.1002/1097-0142(196901)23:1<113::AID-CNCR2820230113>3.0.CO;2-F",
language = "English",
volume = "23",
pages = "113--121",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - The effect of daunomycin on human cells in vivo and in vitro

AU - Whang‐Peng, Jacqueline

AU - Leventhal, Brigid G.

AU - Adamson, John W.

AU - Perry, Seymour

PY - 1969/1/1

Y1 - 1969/1/1

N2 - Cytogenetic and morphologic abnormalities in bone marrow and peripheral blood and biochemical changes in peripheral blood leukocytes were studied after in‐vivo and in‐vitro treatment with daunomycin. Seven patients with acute lymphocytic or granulocytic leukemia were studied; the total dose varied from 80 to 420 mg/m2. The highest percentage of major chromosomal aberrations (80 to 90%) appeared right after treatment in vivo. These aberrations disappeared within 1 or 2 weeks and consisted of chromatid breaks, fragments, chromatid exchanges, ring chromosomes, dicentrics or extensive fragments. Prominent morphologic abnormalities included megaloblastic transformation of both the myeloid and erythroid series and increased cytoplasmic vacuolization. Aneuploid cells lines from two patients showed less change after daunomycin treatment than did normal diploid cells. The daunomycin dose threshold in vitro was narrow: 3 μg/ml of culture caused death of the entire cell population, while 0.03 μg/ml of culture produced little chromosomal damage. The in‐vitro studies on normal human lymphocytes indicate that daunomycin affects RNA and DNA synthesis and that it interferes with the cell cycle during the G2 period. This drug appears to have the unique capacity to delay the onset of mitosis in cells which have already synthesized DNA.

AB - Cytogenetic and morphologic abnormalities in bone marrow and peripheral blood and biochemical changes in peripheral blood leukocytes were studied after in‐vivo and in‐vitro treatment with daunomycin. Seven patients with acute lymphocytic or granulocytic leukemia were studied; the total dose varied from 80 to 420 mg/m2. The highest percentage of major chromosomal aberrations (80 to 90%) appeared right after treatment in vivo. These aberrations disappeared within 1 or 2 weeks and consisted of chromatid breaks, fragments, chromatid exchanges, ring chromosomes, dicentrics or extensive fragments. Prominent morphologic abnormalities included megaloblastic transformation of both the myeloid and erythroid series and increased cytoplasmic vacuolization. Aneuploid cells lines from two patients showed less change after daunomycin treatment than did normal diploid cells. The daunomycin dose threshold in vitro was narrow: 3 μg/ml of culture caused death of the entire cell population, while 0.03 μg/ml of culture produced little chromosomal damage. The in‐vitro studies on normal human lymphocytes indicate that daunomycin affects RNA and DNA synthesis and that it interferes with the cell cycle during the G2 period. This drug appears to have the unique capacity to delay the onset of mitosis in cells which have already synthesized DNA.

UR - http://www.scopus.com/inward/record.url?scp=0014447059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0014447059&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(196901)23:1<113::AID-CNCR2820230113>3.0.CO;2-F

DO - 10.1002/1097-0142(196901)23:1<113::AID-CNCR2820230113>3.0.CO;2-F

M3 - Article

VL - 23

SP - 113

EP - 121

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -